181 related articles for article (PubMed ID: 18760704)
21. Primary non-Hodgkin's lymphoma of the uterus, cervix and parametrium treated by combined immunochemotherapy.
Su CF; Tsai HJ; Kuo C; Chen GD; Lin LY; Huang CC; Luo KH
J Obstet Gynaecol Res; 2008 Aug; 34(4 Pt 2):749-53. PubMed ID: 18840196
[TBL] [Abstract][Full Text] [Related]
22. Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication.
Ghesquières H; Ferlay C; Sebban C; Chassagne C; Carausu L; Gargi T; Favier B; Philip I; Blay JY; Biron P
Hematol Oncol; 2008 Sep; 26(3):139-47. PubMed ID: 18383186
[TBL] [Abstract][Full Text] [Related]
23. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
24. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
Colovic N; Jurisic V; Terzic T; Atkinson HD; Colovic M
Arch Dermatol Res; 2009 Oct; 301(9):689-92. PubMed ID: 19495780
[TBL] [Abstract][Full Text] [Related]
25. Current trends in large cell lymphoma.
Fisher RI; Shah P
Leukemia; 2003 Oct; 17(10):1948-60. PubMed ID: 14513044
[TBL] [Abstract][Full Text] [Related]
26. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
Kim IS; Kim DC; Kim HG; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Kim S; Lee GW
Cancer Genet Cytogenet; 2010 Jan; 196(1):31-7. PubMed ID: 19963133
[TBL] [Abstract][Full Text] [Related]
27. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
28. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
29. Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract.
Rajnics P; Demeter J; Csomor J; Krenács L; Pajor L; Kollár B; Kertész Z; Egyed M
Ann Hematol; 2009 Dec; 88(12):1223-8. PubMed ID: 19352660
[TBL] [Abstract][Full Text] [Related]
30. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.
Chiappella A; Santambrogio E; Castellino A; Nicolosi M; Vitolo U
Expert Rev Hematol; 2017 Aug; 10(8):697-705. PubMed ID: 28665232
[TBL] [Abstract][Full Text] [Related]
31. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
32. [Current treatment for malignant lymphomas].
Usui N
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2191-9. PubMed ID: 18079619
[TBL] [Abstract][Full Text] [Related]
33. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Orciuolo E; Buda G; Pelosini M; Petrini M
Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
[No Abstract] [Full Text] [Related]
35. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Delmonte A; Ghielmini M; Sessa C
Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
[TBL] [Abstract][Full Text] [Related]
36. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
37. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.
Seshadri T; Kuruvilla J; Crump M; Keating A
Biol Blood Marrow Transplant; 2008 Mar; 14(3):259-67. PubMed ID: 18275892
[TBL] [Abstract][Full Text] [Related]
38. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
39. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
40. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
Robledo C; García JL; Caballero D; Conde E; Arranz R; Flores T; Grande C; Rodríguez J; García E; Sáez AI; González M; Gutiérrez NC; Piris MA; Hernández JM;
Cancer; 2009 Aug; 115(16):3728-37. PubMed ID: 19517471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]